S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:VALN

Valneva - VALN Stock Forecast, Price & News

$10.10
+0.30 (+3.06%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.10
$10.38
50-Day Range
$9.80
$21.42
52-Week Range
$9.77
$67.84
Volume
9,522 shs
Average Volume
5,408 shs
Market Capitalization
$592.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.00

Valneva MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
167.3% Upside
$27.00 Price Target
Short Interest
Healthy
0.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Valneva in the last 14 days
Based on 18 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.72) to ($1.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

738th out of 1,095 stocks

Biological Products, Except Diagnostic Industry

121st out of 171 stocks

VALN stock logo

About Valneva (NASDAQ:VALN) Stock

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

VALN Stock News Headlines

Valneva Provides Further Update on its COVID-19 Activities
Valneva (NASDAQ:VALN) Reaches New 52-Week Low at $11.01
The Goldman Sachs Group Downgrades Valneva (NASDAQ:VALN) to Neutral
Valneva (NASDAQ:VALN) Shares Gap Down to $13.48
See More Headlines
Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

VALN Company Calendar

Last Earnings
8/11/2022
Today
10/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VALN
Fax
N/A
Employees
762
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+167.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$411.85 million
Book Value
$3.84 per share

Miscellaneous

Free Float
49,919,000
Market Cap
$592.57 million
Optionable
Not Optionable
Beta
2.74

Key Executives

  • Mr. Thomas Lingelbach (Age 59)
    Chairman of the Management Board, Pres & CEO
    Comp: $745.22k
  • Mr. Franck Grimaud MBA (Age 55)
    Director Gen., Chief Bus. Officer & Member of Management Board
    Comp: $467.35k
  • Mr. Frederic Jacotot (Age 57)
    VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board
    Comp: $366.81k
  • Dr. Juan-Carlos Jaramillo M.D. (Age 51)
    Chief Medical Officer & Member of the Management Board
    Comp: $510.78k
  • Mr. Peter Buhler (Age 51)
    CFO & Management Board Member
  • Mr. Perry Celentano
    Interim Chief Operating Officer
  • Mr. Joshua Drumm Ph.D.
    VP of Investor Relations
  • Ms. Laetitia Bachelot-Fontaine
    VP of Global Communications & European Investor Relations
  • Mr. Gerald Strohmaier
    VP of Human Resource
  • Mr. Christian Taucher
    Head of Global Medical Affairs













VALN Stock - Frequently Asked Questions

Should I buy or sell Valneva stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" VALN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VALN, but not buy additional shares or sell existing shares.
View VALN analyst ratings
or view top-rated stocks.

What is Valneva's stock price forecast for 2022?

4 analysts have issued 1-year target prices for Valneva's stock. Their VALN share price forecasts range from $27.00 to $27.00. On average, they predict the company's stock price to reach $27.00 in the next twelve months. This suggests a possible upside of 167.3% from the stock's current price.
View analysts price targets for VALN
or view top-rated stocks among Wall Street analysts.

How have VALN shares performed in 2022?

Valneva's stock was trading at $55.51 on January 1st, 2022. Since then, VALN stock has decreased by 81.8% and is now trading at $10.10.
View the best growth stocks for 2022 here
.

How were Valneva's earnings last quarter?

Valneva SE (NASDAQ:VALN) posted its earnings results on Thursday, August, 11th. The company reported ($2.86) EPS for the quarter, missing the consensus estimate of ($1.32) by $1.54. The business earned $76.05 million during the quarter, compared to analyst estimates of $21.26 million.

When did Valneva IPO?

(VALN) raised $99 million in an initial public offering (IPO) on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. served as the underwriters for the IPO.

What is Valneva's stock symbol?

Valneva trades on the NASDAQ under the ticker symbol "VALN."

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Valneva's stock price today?

One share of VALN stock can currently be purchased for approximately $10.10.

How much money does Valneva make?

Valneva (NASDAQ:VALN) has a market capitalization of $592.57 million and generates $411.85 million in revenue each year.

How many employees does Valneva have?

The company employs 762 workers across the globe.

How can I contact Valneva?

The official website for the company is valneva.com. The company can be reached via phone at 33-2-28-07-37-10 or via email at investors@valneva.com.

This page (NASDAQ:VALN) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.